Actively Recruiting
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2024-08-13
456
Participants Needed
1
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.
CONDITIONS
Official Title
Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be 16 years of age or older
- Patients receiving haploidentical allogeneic hematopoietic stem cell transplantation
- Patients must sign an informed consent form before the research begins
You will not qualify if you...
- Patients who have had tandem transplantation or multiple transplantations
- Patients with mental or other medical conditions that prevent compliance with research treatment and monitoring
- Patients who are ineligible for the study or would face great risk by participating
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
Y
Yahui Feng, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here